Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.39 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3280391 | 1.00 | ALDH1A1 (0.45) | ALDH1A1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL17934312 | 1.00 | ALDH1A1 (0.45) | ALDH1A1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL18161021 | 0.94 | ALDH1A1 (0.42) | ALDH1A1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL18160998 | 0.94 | ALDH1A1 (0.42) | ALDH1A1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL18161020 | 0.94 | ALDH1A1 (0.42) | ALDH1A1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL17930122 | 0.94 | ALDH1A1 (0.42) | ALDH1A1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL17930121 | 0.94 | ALDH1A1 (0.42) | ALDH1A1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL18161002 | 0.93 | CYP2D6 (0.41) | ALDH1A1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL16830432 | 0.93 | CYP2D6 (0.41) | ALDH1A1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL16846654 | 0.93 | CYP2D6 (0.41) | ALDH1A1CYP2D6CYP3A4TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376099-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS AG (CH) | 2024-11-14 | — | — | US | disclosed |
| EP-4059934-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | Novartis AG (CH) | 2022-09-21 | — | — | EP | disclosed |
| EP-3057946-A2 | SYNTHESIS OF DIACIDS, DIALDEHYDES, OR DIAMINES FROM THF-DIOLS | Archer Daniels Midland Co. (US) | 2016-08-24 | — | — | EP | disclosed |
| US-20160207894-A1 | Synthesis of Diacids, Dialdehydes, or Diamines from THF-Diols | ARCHER DANIELS MIDLAND CO (US) | 2016-07-21 | — | — | US | disclosed |
| US-20160207894-A1 | Synthesis of Diacids, Dialdehydes, or Diamines from THF-Diols | ARCHER DANIELS MIDLAND CO (US) | 2016-07-21 | — | — | US | disclosed |
| WO-2015057365-A2 | SYNTHESIS OF DIACIDS, DIALDEHYDES, OR DIAMINES FROM THF-DIOLS | ARCHER DANIELS MIDLAND COMPANY (US) | 2015-04-23 | — | — | WO | disclosed |
| US-8129371-B2 | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors | WYETH LLC (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129371-B2 | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors | WYETH LLC (US) | 2012-03-06 | — | — | US | disclosed |
| WO-2009052145-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
| EP-0863905-B1 | IMIDAZOLE LIPOXYGENASE INHIBITORS | PFIZER (US) | 2000-11-29 | — | — | EP | disclosed |
| US-6037355-A | ANTIINFLAMMATORY AGENTS AND ANTIALLERGENS; CARDIOVASCULAR DISORDERS | PFIZER INC (US) | 2000-03-14 | — | — | US | disclosed |
| US-3959308-A | Substituted naphtho pyrazoles | SANDOZ, INC. (US) | 1976-05-25 | — | — | US | disclosed |
| US-3953596-A | 8-Oxa-3-azabicyclo(3.2.1)octane analgesic compositions and method of alleviating pain in animals | ICI UNITED STATES INC. (US) | 1976-04-27 | — | — | US | disclosed |
| US-3932430-A | Substituted indeno, naphtho and cyclohepta pyrazoles | SANDOZ, INC. (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376099-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | TLR3, TLR1, TLR4 | ALDH1A1 4528/4885CYP2D6 4703/4885CYP3A4 4771/4885 |
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | MTOR, PIK3CA, PIK3CD | ALDH1A1 2453/4885CYP2D6 713/4885CYP3A4 843/4885 |
| US-20160207894-A1 | Synthesis of Diacids, Dialdehydes, or Diamines from THF-Diols | DHODH, MTHFD2, DHPS | ALDH1A1 200/4885CYP2D6 675/4885CYP3A4 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.